This isn't shaping up to be a banner week for BioNTech (NASDAQ: BNTX). The bellwether coronavirus stock took it on the chin Monday and was being similarly battered by investors Tuesday because of post-earnings analyst price target cuts. Following second-quarter results that disappointed many investors, several analysts recalibrated their takes on BioNTech stock Tuesday.
Novavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market trading after management slashes revenue guidance for 2022 by half.